Transactions
Life Sciences Advisory Firm Facilitating Strategic Business Transactions
Shadow Lake Group specializes in life sciences strategic advisory services. We fulfill the need for third party representation to facilitate an expedited transaction process leading to more favorable business outcomes.
Collectively, the Shadow Lake team has more than 80 years of experience and has completed $16.5B+ in a wide range of complex transactions from M&As, divestitures, asset purchases, licensing, commercial strategies, business modelling and valuations. Our extensive global networks and comprehensive due diligence process lead to more favorable business outcomes.
Since inception, Shadow Lake has closed 22 transactions valued at $2.5B+. Clients have trusted Shadow Lake to successfully complete their complex transactions.
A Few of Our Transactions
Cheplapharm & Lilly
$1.4 Billion
Global ZYPREXA™ Asset Purchase
Immedica & Actinium
$452 Million
Iomab-B In-license for Europe & MENA
Isofol & Solasia
$100 Million
Arfolitixorin Out-license for Japanese Market
HLS Therapeutics & Novartis
$300 Million+
Clozaril U.S./Canadian Market
HLS Therapeutics & Amarin
$65 Million
In-license for Canadian Market
HLS Therapeutics & Indivior
$45 Million
PERSERIS™ In-license for Canadian Market
Isofol & Paladin
$23 Million
Arfolitixorin Out-licencse for Canadian Market
Legacy Pharma & Roche
Deal terms undisclosed
Acquisition of Intermune and U.S. Rights to ESBRIET™
Legacy Pharma & Sebela
Deal terms undisclosed
Commercial Asset Bundle Purchase for U.S. Market
Aytu BioPharma & Lupin
Deal terms undisclosed
ADHD Product License for Canadian Market
Numedicus & AMO Pharma
Deal terms undisclosed
Global License for Orphan Drug
Vasomune & AnGes
Deal terms undisclosed
Global License for Preclinical Drug
Collaborate with Us!
Shadow Lake Group is well positioned to navigate through every step of a complex transaction to deliver customized strategic advisory services.